Drug profile · INN
benzquinamide hydrochloride
EMETE-CON
benzquinamide hydrochloride (EMETE-CON) is a dopamine d2 receptor modulator. Route of administration: rectal. Current US regulatory status: approved.
Drug details — benzquinamide hydrochloride
- US status
- approved
- Class
- —
- Route
- RECTAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
benzquinamide hydrochloride (EMETE-CON) is a dopamine d2 receptor modulator. Route of administration: rectal. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine D2 receptor modulator
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is benzquinamide hydrochloride?
benzquinamide hydrochloride (EMETE-CON) is a dopamine d2 receptor modulator. Route of administration: rectal. Current US regulatory status: approved.
What is the brand name for benzquinamide hydrochloride?
EMETE-CON is a marketed brand name for benzquinamide hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of benzquinamide hydrochloride?
benzquinamide hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.